Novartis shares fall more than 10% as del-desiran trial marks third setback in a week
Del-desiran trial results disappointed investors on Tuesday, sending Novartis (NVS) shares down more than 10% and marking the company's third clinical setback in a single week. Three misses compressed into that window carry their own signal beyond any individual dataset.
Key takeaways
- Novartis shares fell more than 10% on Tuesday after disappointing del-desiran trial results.
- The del-desiran miss was Novartis's third clinical setback within a single week.
- The market's concern has shifted from individual project risk to the strength and timing of Novartis's broader pipeline.
- The session's decline reflected both the specific del-desiran readout and the compounding effect of three consecutive disappointments.
- Investors are watching for any forthcoming Novartis clinical readout and whether management addresses the string of results.
Del-desiran trial results disappointed investors on Tuesday, sending Novartis (NVS) shares down more than 10% and marking the company's third clinical setback in a single week. Three misses compressed into that window carry their own signal beyond any individual dataset.
One trial failure registers as project-level risk. Three in quick succession shifts the market's attention to a broader question: what the pipeline can offer as a counterweight, and how soon. Del-desiran is the latest entry in that sequence, and the tape has now had three consecutive data points to price.
The session's decline reflects both the specific del-desiran read and the compounding effect of the pattern surrounding it. The setup for NVS from here depends on how the market assigns probability to remaining pipeline catalysts after a week that produced three straight disappointments with nothing on the other side of the ledger.
What to watch: any forthcoming clinical readout from Novartis, and whether management directly addresses the current string of results.
Filed by the macro desk of MarketPR on September 8, 2026. Source: cnbc.com. Indicative figures are not investment advice.